Needle-free platform Crossject offers ZENEO, a needle-free autoinjector platform for emergency medications, presenting a sales opportunity to expand into hospitals, emergency response teams, and home healthcare suppliers seeking safer, rapid administration options.

Strategic partnerships Recent and ongoing collaborations with U.S. BARDA, Heights Capital, and Cenexi indicate a proven appetite for strategic partnerships and co-development funding, suggesting opportunities for co-investment or licensing deals to accelerate product adoption.

Regulatory momentum Advanced regulatory development for ZEPIZURE with federal backing signals potential for faster market access and credibility with payers and distributors, enabling you to position Crossject for reimbursement discussions and market entry in new territories.

Diversified indications Beyond epinephrine, Crossject targets allergic shocks, adrenal insufficiencies, opioid overdose and asthma rescue therapies, which opens up multiple high-need market segments for portfolio expansion and cross-sell to existing customers.

Small but scalable With a lean team and sub-$1M revenue yet substantial funding, Crossject appears poised for scalable partnerships, licensing deals or contract manufacturing arrangements that can leverage their ZENEO platform without large upfront sales investments.